RECORD // Company

Latigo Biotherapeutics, Inc.

Built 2026-11-21T06:00:54Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)
Matched by name only, not merged (5)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • Latigo Biotherapeutics, Inc · Ca business · same registered legal name as 'Latigo Biotherapeutics, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • Latigo Biotherapeutics · Ctgov · exact name match to 'Latigo Biotherapeutics, Inc.' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare
  • LATIGO BIOTHERAPEUTICS INC · Epa echo · same registered legal name as 'Latigo Biotherapeutics, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • LATIGO BIOTHERAPEUTICS INC · Epa echo · same registered legal name as 'Latigo Biotherapeutics, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • LATIGO BIOTHERAPEUTICS, INC. · Epa echo · same registered legal name as 'Latigo Biotherapeutics, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare

3 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-05 · accession 0001193125-26-448582

ItemValuePeriodFormFiledAccessionReport
Net income (loss)$-20,949,0003 months ended 2026-09-3010-Q2026-11-050001193125-26-4485822026-11-21 06:00 UTCReport an error
Interest expense$699,0003 months ended 2026-09-3010-Q2026-11-050001193125-26-4485822026-11-21 06:00 UTCReport an error
Cash and cash equivalents$401,241,000at 2026-09-3010-Q2026-11-050001193125-26-4485822026-11-21 06:00 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Revenue.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0002056611
Ticker
LTGO
EIN
832625838
CUSIP
517954103
Record ID
sx:sec:0002056611

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

13 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-18SEC EDGAR company profile2026-11-21 06:00 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-18SEC EDGAR company profile2026-11-21 06:00 UTCReport an error
State of incorporationDE2026-11-18SEC EDGAR company profile2026-11-21 06:00 UTCReport an error
Fiscal year end (MMDD)12312026-11-18SEC EDGAR company profile2026-11-21 06:00 UTCReport an error
Business address1300 RANCHO CONEJO BLVD., SUITE 305, THOUSAND OAKS, CA2026-11-18SEC EDGAR company profile2026-11-21 06:00 UTCReport an error
ExchangesNasdaq2026-11-18SEC EDGAR company profile2026-11-21 06:00 UTCReport an error
Form D total offering amount (D filed 2025-02-13)$149,999,9902025-02-13D2026-11-21 06:00 UTCReport an error
Form D total amount sold (D filed 2025-02-13)$49,999,9952025-02-13D2026-11-21 06:00 UTCReport an error
Form D industry groupBiotechnology2025-02-13D2026-11-21 06:00 UTCReport an error
Form D revenue rangeDecline to Disclose2025-02-13D2026-11-21 06:00 UTCReport an error
Form D date of first sale2025-01-282025-02-13D2026-11-21 06:00 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-05)On November 5, 2026, Latigo Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. All of the information furnished in this Item 2.02 and Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act…2026-11-05SEC EDGAR 8-K 0001193125-26-448537 (text as filed, excerpt)2026-11-21 06:00 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-09-03)On September 3, 2026, Latigo Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. All of the information furnished in this Item 2.02 and Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act…2026-09-03SEC EDGAR 8-K 0001193125-26-381912 (text as filed, excerpt)2026-11-21 06:00 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.